Cancer and disease-focused biotechnology group Celularity said Friday it's going public through a tie-up with blank-check company GX in a deal valued at $1.7 billion and guided by Cooley and Skadden....
Want to continue reading?
Take a 7 Day FREE Trial
Unlock these benefits today when you sign-up for a FREE 7-day trial:
- Gain a competitive edge with exclusive data visualization tools to tailor to your practice
- Stay informed with daily newsletters and custom alerts across 14+ coverage areas relevant to you
- Streamline your business of law needs with integrated news and research in a single destination
Already have an account? Sign In Now
